Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute.
Dai ChiharaErich P HuangShanda R FinniganLisa M CordesNebojsa SkorupanYoko FukudaLawrence V RubinsteinSusan Percy IvyJames H DoroshowLoretta J NastoupilChristopher R FlowersNaoko TakebePublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)
Over time, the ORR and CR rates in phase I trials for hematologic malignancy have improved meaningfully, whereas the rate of toxicity-related death remains stable. This study provides broad experience that physicians can use when discussing the potential outcomes for patients with hematologic malignancy considering participation in phase I trials.